What is claimed is:

1. A method to stimulate the immune system in vitro with an antigen in a formulation without interfering with the current preprogrammed response of the immune system to that antigen by means of administering the antigen in an otherwise immunoneutral formulation.

2. A method to modulate an undesired current status of the immune system in an individual by:
   a) evaluating the current immune response to an antigen in vitro according to the method of claim 1.
   b) deciding on a therapeutic formulation suitable for specific immunomodulation away from of the individual's current unwanted immune response.

3. A formulation that is immunoneutral to the immune system of an individual and capable of solubilizing hydrophobic antigens.

4. A formulation according to claim 3 where immunoneutral hydrophobic solvent is species specific Serum Albumin.

5. A formulation according to claim 4 including an antigen for stimulation of the immune system.

6. A formulation for antigen specific downregulation of inflammatory responses comprising at least two of the ingredients antigen and alum.

7. A formulation according to claim 5 or 6, where the antigen is of at least one from the group of ICA512 (IA2), ICA512B (IA2B), insulin, insulin B-chain, proinsulin, Hsp60, Hsp65, P277, ICA69, Glima38, GAD 65, GAD67, SOX13, Imogen 38, Sulfatide,

MBP, MOG, Collagen II, 21-Ohase, TPO, allergens, transplant antigens, cancer antigens, or parts, peptides or altered peptide ligands thereof.

8. A kit for evaluation of lymphocyte reaction to antigen comprising a formulation according to claim 7.

9. A therapeutic comprising a formulation according to claim 7.

10. A therapeutic according to claim 9 where concentrations of antigen for in vitro stimulation typically is between 1-100 micrograms per ml.

11. A therapeutic according to claim 9 where concentrations of antigen for in vitro stimulation typically is between 5-40 micrograms per ml.

12. A therapeutic according to claim 9 where the subcutaneous administration of antigen for in vivo stimulation typically is between 0.1 micrograms per ml.

13. A therapeutic according to claim 9 where intravenous administration of antigen for in vivo stimulation typically is between 0.1-5 mgs/kg.

14. A method to stimulate the immune system in vitro with an antigen in a formulation without interfering with the current preprogrammed response of the immune system to that antigen by means of administering the antigen in an otherwise immunoneutral formulation.

15. A method to modulate an undesired current status of the immune system in an individual by:

a) evaluating the current immune response to an antigen in vitro according to the method of claim 1.

b) deciding on a therapeutic formulation suitable for specific immunomodulation away from of the individual's current unwanted immune response.

16. A formulation that is immunoneutral to the immune system of an individual and capable of solubilizing hydrophobic antigens.

17. A formulation according to claim 3 where immunoneutral hydrophobic solvent is species specific Serum Albumin.

18. A formulation according to claim 4 including an antigen for stimulation of the immune system.

19. A formulation for antigen specific downregulation of inflammatory responses comprising at least two of the ingredients antigen and alum.

20. A formulation according to claim 5 or 6, where the antigen is of at least one from the group of ICA512 (IA2), ICA512B (IA2B), insulin, insulin B-chain, proinsulin, Hsp60, Hsp65, P277, ICA69, Glima38, GAD 65, GAD67, SOX13, Imogen 38, Sulfatide, MBP, MOG, Collagen II, 21-Ohase, TPO, allergens, transplant antigens, cancer antigens, or parts, peptides or altered peptide ligands thereof.

21. A kit for evaluation of lymphocyte reaction to antigen comprising a formulation according to claim 7.

22. A therapeutic comprising a formulation according to claim 7.

23. A therapeutic according to claim 9 where concentrations of antigen for in vitro stimulation typically is between 1-100 micrograms per ml.

24. A therapeutic according to claim 9 where concentrations of antigen for in vitro stimulation typically is between 5-40 micrograms per ml.

25. A therapeutic according to claim 9 where the subcutaneous administration of antigen for in vivo stimulation typically is between 0.1 micrograms per ml.

26. A therapeutic according to claim 9 where intravenous administration of antigen for in vivo stimulation typically is between 0.1-5 mgs/kg.